A company my colleagues and I have worked with since 2014, first as company counsel, and later, when firm-level conflicts considerations required it, as investor counsel for one of the founders working shoulder-to-shoulder with dedicated company counsel, recently closed its initial public offering. I am leaving the name out of this post for confidentiality reasons; the identity of the company is not the point. The arc is.

That arc runs roughly a dozen years, from a sponsored research conversation inside a university lab to a Nasdaq closing bell and covers most of what an emerging company practice can throw at you in between. While there were countless other lessons learned, one of the major takeaways was that the legal infrastructure laid down in a company’s earliest months is what can determine whether the later rounds, and an exit, are clean or chaotic.

The “Valley of Death” Is a Legal Story, Too

The “venture valley of death” is usually described as a capital gap. While that may be correct, it typically ignores the parallel legal terrain. Sponsored research arrangements that do not cleanly assign IP. Founder equity grants papered six months too late. Inbound NDAs signed without anyone reading the use-restriction clause. Convertible instruments stacked on top of each other until the cap table looks like a Jenga tower. Any one of those situations can sink a Series A diligence process, never mind an S-1 review.

What “Cradle to IPO” Actually Looked Like

We developed the relationship before there was a company. The technology was still in the lab, and the founders were navigating sponsored research dynamics with their academic institution. From there, our work moved through the predictable but consequential milestones: entity formation, founder restricted-stock arrangements, an early board structure that could actually function, the form NDA and consulting agreement every emerging company needs but few have papered properly, the initial slate of employee confidentiality and invention-assignment agreements, and the first priced round of preferred stock.

When conflicts considerations later required us to step back from formal company representation, we did not step out of the picture completely, we just shifted seats. We continued through Seed, Series A, Series B, and Series C from the investor side, working alongside replacement company counsel and keeping continuous read on the cap table, the governance stack, and the commercial agreements that would eventually have to survive an S-1 review. By the time the company filed, the foundational paper supported a public-company review instead of working against it. That is not an accident, and it is not luck.

Lex’s DNA: Built by Venture and PE, Run with AI

Lex Generalis was not a generalist firm that drifted into venture work. It was built by venture capital and private equity practitioners at its core, and that orientation shows up in the two places inventors and investors care about most.

First, transaction quarterbacking. The hardest part of an early-stage financing is rarely the drafting. It is running the process and keeping founders, investors, board members, auditors, and outside professionals moving in a single direction without losing the plot. We treat quarterbacking as substantive lawyering, not project management.

Second, cost discipline. Emerging companies and the funds backing them are sensitive to legal spend in a way large-cap clients are not. We have built our practice on a frank assumption: a meaningful fraction of the work in this space is repeatable, and we deliberately use AI tooling carefully, and always under attorney oversight, to accelerate the repeatable parts. The result is the same depth of substantive judgment a founder or fund would get from a much larger shop, at a cost that matches the stage. The same logic applies to the day-to-day business matters such as vendor paper, employment agreements, governance hygiene, fund operations and more that quietly consume more legal budget than founders and managers expect.

The Hybrid Lens

We sit at the intersection of emerging-company counsel and investment management counsel. We represent the founders building these businesses, and we represent the investors writing the checks. When we paper a SAFE or a Series Seed financing, we are thinking about how that instrument will read three rounds and an exit from now, because we have sat on both sides of that diligence call.

The Takeaway

Not every early-stage or growth-stage company becomes a publicly listed issuer. Most will not. But the discipline of getting the foundational work right, and the relationship discipline to stay close through reorganizations, conflicts moves, and capital structure changes, is what helps give a company the option. When founders, investors, and counsel align early and stay aligned, outcomes like the one I referenced at the beginning of this post become possible.

If you are building something, or backing someone who is, that is the kind of relationship worth having from day one.

Disclaimer: This post is published by Lex Generalis LLC and reflects the views of the author. It is provided for general informational purposes only, does not constitute legal advice, and does not create an attorney-client relationship between the reader and Lex Generalis LLC or any of its attorneys. The illustrative client engagement described in this post is drawn from the author’s general professional experience; specific identifying details have been omitted for confidentiality reasons. Prior results do not guarantee or predict a similar outcome in any future matter; every engagement turns on its own facts and circumstances. Readers should consult qualified counsel regarding their specific situation.

Attorney Advertising. This material may be considered attorney advertising in some jurisdictions.